FDA aprueba dispositivo de Abbott para tratar fugas en válvulas cardíacas reemplazadas
- Abbott recibió el 28 de octubre de 2026 la autorización de la FDA para su dispositivo Amplatzer Paraclose PVL Occluder.
- Es el primer y único dispositivo transcatéter autorizado en Estados Unidos para tratar fugas paravalvulares sin repetir la cirugía cardíaca.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.